Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Lingamneni AnilaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-184Price:$84.88
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:Simon, ChristopherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-38,900Price:--
-
Nov 01, 2023 (filed on Nov 03, 2023)Insider Name:Galvin RoyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-160Price:$86.39
-
Oct 20, 2023 (filed on Oct 24, 2023)Insider Name:Basil Michelle LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-197Price:$89.05
-
Oct 20, 2023 (filed on Oct 24, 2023)Insider Name:Strong Stewart WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-120Price:$89.05
-
Sep 15, 2023 (filed on Sep 18, 2023)Insider Name:Miller Laurie A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-209Price:$90.11
-
Sep 12, 2023 (filed on Sep 13, 2023)Insider Name:Strong Stewart WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-228Price:$90.65
-
Sep 11, 2023 (filed on Sep 13, 2023)Insider Name:Lingamneni AnilaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,305Price:$90.00
-
Sep 05, 2023 (filed on Sep 07, 2023)Insider Name:Dockendorff Charles JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,215Price:$87.68
-
Aug 04, 2023 (filed on Aug 08, 2023)Insider Name:Bryant Diane MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,226Price:--
Filings by filing date
-
Apr 15, 2024 (filed on Apr 17, 2024)Insider Name:Lingamneni AnilaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-184Price:$84.88
-
Mar 11, 2024 (filed on Mar 13, 2024)Insider Name:Simon, ChristopherOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-38,900Price:--
-
Nov 01, 2023 (filed on Nov 03, 2023)Insider Name:Galvin RoyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-160Price:$86.39
-
Oct 20, 2023 (filed on Oct 24, 2023)Insider Name:Basil Michelle LOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-197Price:$89.05
-
Oct 20, 2023 (filed on Oct 24, 2023)Insider Name:Strong Stewart WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-120Price:$89.05
-
Sep 15, 2023 (filed on Sep 18, 2023)Insider Name:Miller Laurie A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-209Price:$90.11
-
Sep 11, 2023 (filed on Sep 13, 2023)Insider Name:Lingamneni AnilaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,305Price:$90.00
-
Sep 12, 2023 (filed on Sep 13, 2023)Insider Name:Strong Stewart WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-228Price:$90.65
-
Sep 05, 2023 (filed on Sep 07, 2023)Insider Name:Dockendorff Charles JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-10,215Price:$87.68
-
Aug 04, 2023 (filed on Aug 08, 2023)Insider Name:Bryant Diane MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:2,226Price:--
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 125 Summer Street BOSTON MA 02110 |
Tel: | 1-781-3569763 |
Website: | https://www.haemonetics.com |
IR: | See website |
Key People | ||
Christopher A. Simon President, Chief Executive Officer, Director | James C. D'arecca Executive Vice President, Chief Financial Officer | Roy Galvin President - Global Plasma and Blood Center |
Stewart W. Strong President - Global Hospital | Laurie A. Miller Chief Human Resource Officer, Senior Vice President | Anila Lingamneni Executive Vice President, Chief Technology Officer |
Michelle L. Basil Executive Vice President, General Counsel | Josep L. Llorens Executive Vice President - Global Manufacturing and Supply Chain |
Business Overview |
Haemonetics Corporation is a global healthcare company. The Company provides a suite of medical products and solutions for customers to help them improve patient care and reduce the cost of healthcare. Its technology addresses three medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Its segments include Plasma, Blood Center, and Hospital. Its Plasma segment offers automated plasma collection systems, donor management software, and supporting software solutions that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to collect and separate blood components for transfusions. Its Hospital segment provides patient care and has four product lines: hemostasis management, vascular closure, cell salvage, and transfusion management. Its portfolio also includes fiber optic sensor technology in the interventional cardiology market. |
Financial Overview |
For the 39 weeks ended 30 December 2023, Haemonetics Corporation revenues increased 12% to $965.8M. Net income increased 13% to $97.2M. Revenues reflect Plasma segment increase from $136.6M to $426.9M, Hospital segment increase from $93.9M to $316.7M, Blood Center segment increase from $76.8M to $207.8M, United States segment increase from $224.1M to $724.2M, Europe segment increase from $39.1M to $115.1M, Asia segment increase from $25.5M to $80.7M. |
Employees: | 3,034 as of Apr 1, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $4,915M as of Dec 30, 2023 |
Annual revenue (TTM): | $1,270M as of Dec 30, 2023 |
EBITDA (TTM): | $325.50M as of Dec 30, 2023 |
Net annual income (TTM): | $126.57M as of Dec 30, 2023 |
Free cash flow (TTM): | $128.75M as of Dec 30, 2023 |
Net Debt Last Fiscal Year: | $676.61M as of Dec 30, 2023 |
Shares outstanding: | 50,786,117 as of Feb 6, 2024 |
Index Membership: | S&P 400 Mid Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |